ResMed (RMD) : Analyst Rating Update

ResMed (RMD) has an average broker rating of 3.28, which is interpreted as a Hold, as rated by 9 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 3 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

ResMed (RMD) : The most positive equity analysts on ResMed (RMD) expects the shares to touch $64, whereas, the least positive believes that the stock will trade at $44 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $56.2 with an expected fluctuation of $6.24 from the mean.

ResMed (NYSE:RMD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $63.42 and $63.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $64.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $63.91, notching a gain of 0.49% for the day. The total traded volume was 1,052,509 . The stock had closed at $63.60 on the previous day.

Also, Needham downgrades its rating on ResMed (NYSE:RMD). Analysts at the Needham have a current rating of Underperform on the shares. The shares were previously rated Hold. The rating by the firm was issued on June 27, 2016. The company shares have rallied 13.55% from its 1 Year high price. On Jun 23, 2016, the shares registered one year high at $63.85 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $59.75 and the 200 Day Moving Average price is recorded at $57.66.

ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.